Class: Proton-pump Inhibitors
VA Class: GA900
Chemical Name: 2-[[[3-Methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole
Molecular Formula: C16H14F3N3O2S
CAS Number: 103577-45-3
Brands: Prevacid, Prevpac
Uses for Lansoprazole
Gastroesophageal Reflux (GERD)
Short-term treatment of symptomatic GERD (e.g., heartburn).1
Treatment of Helicobacter pylori infection and duodenal ulcer disease.1 134 Used in conjunction with amoxicillin and clarithromycin (triple therapy) or clarithromycin (dual therapy);1 134 has been used in other multidrug regimens†.126 129 131 135
Maintenance therapy following duodenal ulcer healing.1
Short-term treatment and symptomatic relief of active benign gastric ulcer.1
NSAIA-induced Gastric Ulcer
Risk reduction in patients with history of gastric ulcer who require NSAIA treatment.1
Pathologic GI Hypersecretory Conditions
Long-term treatment of pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome with or without multiple endocrine adenoma).1
Crohn’s Disease-associated Ulcers
Some evidence for use of proton-pump inhibitors (e.g., omeprazole) for gastric acid suppressive therapy as an adjunct in the management of upper GI Crohn’s disease†, including esophageal, gastroduodenal, and jejunoileal disease.162 163 164 166 167
Lansoprazole Dosage and Administration
Alternatively, open capsule and sprinkle contents on 1 tablespoonful of compatible foods (e.g., applesauce, Ensure pudding, cottage cheese, yogurt, strained pears) or mix with about 60 mL of appropriate juice (e.g., apple juice, orange juice, tomato juice); swallow immediately without chewing.1 If mixed with juice, rinse glass with ≥120 mL juice and swallow immediately to ensure complete dose ingestion.1 Do not mix with other foods or liquids.1
Manufacturer recommends swallowing capsules for self-medication with a glass of water.191
Orally Disintegrating Tablets
To administer using an oral syringe, place 15- or 30-mg tablet in oral syringe, draw up about 4 or 10 mL, respectively, of water in the syringe, gently shake syringe to ensure rapid dispersal of particles, and administer within 15 minutes.1 To ensure complete consumption of dose, draw up an additional 2 mL (15-mg dose) or 5 mL (30-mg dose) of water in syringe, mix gently, and administer remaining contents.1
Capsules: Open capsule and mix contents with about 40 mL apple juice and administer immediately (within 3–5 minutes) through NG tube; flush tube with additional apple juice.1 127 Do not mix with other liquids.1
Orally disintegrating tablets: Place 15- or 30-mg tablet in syringe, draw up about 4 or 10 mL, respectively, of water in the syringe, gently shake syringe to ensure rapid dispersal of particles, and administer within 15 minutes through NG tube (8 French or larger).1 Draw up an additional 5 mL of water in syringe, mix gently, and flush NG tube with syringe contents.1
Children 1–11 years of age: In those weighing ≤30 kg, 15 mg once daily for up to 12 weeks.1 In those weighing >30 kg, 30 mg once daily for up to 12 weeks.1 Dosage has been increased up to 30 mg twice daily after ≥2 weeks in patients remaining symptomatic.1
Children 12–17 years of age: 15 mg daily for up to 8 weeks.1
Treatment of Erosive EsophagitisOral
Children 1–11 years of age: In those weighing ≤30 kg, 15 mg once daily for up to 12 weeks.1 In those weighing >30 kg, 30 mg once daily for up to 12 weeks.1 Dosage has been increased up to 30 mg twice daily after ≥2 weeks in patients remaining symptomatic.1
Children 12–17 years of age: 30 mg daily for up to 8 weeks.1
Chronic, lifelong therapy with proton-pump inhibitor is appropriate for many GERD patients.156
15 mg once daily for up to 8 weeks.1
Treatment of Erosive EsophagitisOral
Maintenance of Healing of Erosive EsophagitisOral
Self-medication for Frequent HeartburnOral
15 mg once daily in the morning for 14 days.191 Do not exceed recommended dosage or duration; do not administer more than 1 course every 4 months.191 May relieve symptoms within 24 hours, but 1–4 days may be required for complete relief.191
Treatment of Active Duodenal UlcerOral
Treatment of Helicobacter pylori Infection and Duodenal UlcerOral
Dual therapy: 30 mg every 8 hours for 14 days in conjunction with amoxicillin.1
Maintenance of Duodenal Ulcer HealingOral
Benign Gastric UlcerOral
NSAIA-induced Gastric Ulcer
30 mg once daily for 8 weeks.1
Pathologic GI Hypersecretory Conditions (e.g., Zollinger-Ellison Syndrome)
60 mg once daily initially.1 2 24 25 28 Adjust dosage according to patient response and tolerance; continue therapy as long as necessary.1 2 3 5 May require dosages of up to 90 mg twice daily.1 3 5 10 24 25 26 27 43 Administer daily dosages >120 mg in divided doses.1 7 43 Patients with Zollinger-Ellison syndrome have been treated for up to 4 years.1
Cautions for Lansoprazole
Clostridium difficile Infection
Proton-pump inhibitors associated with possible increased (1.4–2.75 times) risk of Clostridium difficile infection, including C. difficile-associated diarrhea and colitis (CDAD; also known as antibiotic-associated diarrhea and colitis or pseudomembranous colitis).335 336 339 340 Many patients also had other risk factors for CDAD.335 May be severe; colectomy and, rarely, death reported.335
Use the lowest effective dosage and shortest duration of therapy appropriate for the patient's clinical condition.335
Consider CDAD if persistent diarrhea develops and manage accordingly; initiate supportive therapy (e.g., fluid and electrolyte management), anti-infective therapy directed against C. difficile (e.g., metronidazole, vancomycin), and surgical evaluation as clinically indicated.335 336
Each 15- or 30-mg Prevacid Solu-Tab™ orally disintegrating tablet contains aspartame, which is metabolized in the GI tract to provide 2.5 or 5.1 mg of phenylalanine, respectively.1
Several observational studies suggest that use of proton-pump inhibitors, particularly in high dosages (i.e., multiple daily doses) and/or for prolonged periods of time (i.e., ≥1 year), may be associated with increased risk of osteoporosis-related fractures of the hip, wrist, or spine.1 178 300 301 302 303 304 305 Magnitude of risk is unclear;178 300 301 302 303 304 305 310 causality not established.305 FDA is continuing to evaluate this safety concern.305
Individuals at risk for osteoporosis-related fractures should receive an adequate intake of calcium and vitamin D; assess and manage these patients’ bone health according to current standards of care.1 178 303 305 307
Hypomagnesemia, symptomatic and asymptomatic, reported rarely in patients receiving long-term therapy (≥3 months or, in most cases, >1 year) with proton-pump inhibitors, including lansoprazole.1 317 318 319 320 321 322 323 324 325 326 327 328 329 330 Serious adverse effects include tetany, seizures, tremors, carpopedal spasm, arrhythmias (e.g., atrial fibrillation, supraventricular tachycardia), and abnormal QT interval.1 318 319 321 322 323 325 327 328 329 Paresthesia, muscle weakness, muscle cramps, lethargy, fatigue, and unsteadiness may occur.319 320 321 325 330 Most patients required magnesium replacement and discontinuance of the proton-pump inhibitor.1 317 319 321 322 323 324 325 326 327 330 Hypomagnesemia resolved within 1 week (median) following discontinuance and recurred within 2 weeks (median) of rechallenge.327
In patients expected to receive long-term proton-pump inhibitor therapy or in patients currently receiving digoxin or drugs that may cause hypomagnesemia (e.g., diuretics), consider measuring serum magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter.1 319 326 327 328 330
Use of Combination Preparations
When kits containing lansoprazole and other agents (anti-infectives) are used, consider the cautions, precautions, and contraindications associated with the concomitant agent(s).134
Safety and efficacy of oral lansoprazole established for short-term treatment of symptomatic GERD and erosive esophagitis in patients 1–17 years of age.1
Oral lansoprazole is not recommended in infants <1 year of age; the drug was no more effective than placebo in a controlled study in infants 1 month to <1 year of age with symptomatic GERD.1
Safety and efficacy for self-medication of frequent heartburn not established in children <18 years of age.191
No substantial differences in efficacy and safety of oral lansoprazole in geriatric patients relative to younger adults.1
Common Adverse Effects
Interactions for Lansoprazole
Drugs Metabolized by Hepatic Microsomal Enzymes
Drugs that Cause Hypomagnesemia
Potential pharmacologic interaction (possible increased risk of hypomagnesemia).327 Consider monitoring magnesium concentrations prior to initiation of prescription proton-pump inhibitor therapy and periodically thereafter.1 327 (See Hypomagnesemia under Cautions.)
Antiretroviral treatment-naive patients: If a proton-pump inhibitor is used concomitantly with atazanavir, administer ritonavir-boosted atazanavir (atazanavir 300 mg and ritonavir 100 mg once daily with food); administer the proton-pump inhibitor approximately 12 hours before ritonavir-boosted atazanavir179 180
Certain CYP2C19 inhibitors (e.g., omeprazole, esomeprazole) reduce exposure to clopidogrel’s active metabolite and decrease platelet inhibitory effects; potentially may reduce clopidogrel’s clinical efficacy.186 224 225 228 232 233 236 311 350
Manufacturer of lansoprazole states clopidogrel dosage adjustment not required if used with recommended lansoprazole dosages1
American College of Cardiology Foundation/American College of Gastroenterology/American Heart Association (ACCF/ACG/AHA) states that GI bleeding risk reduction with concomitant proton-pump inhibitor in patients with risk factors for GI bleeding (e.g., advanced age; concomitant use of warfarin, corticosteroids, or NSAIAs); H. pylori infection) may outweigh potential reduction in cardiovascular efficacy of antiplatelet treatment associated with a drug-drug interaction.311 In patients without such risk factors, ACCF/ACG/AHA states that risk/benefit balance may favor use of antiplatelet therapy without a proton-pump inhibitor.311
If concomitant therapy with a proton-pump inhibitor and clopidogrel is deemed necessary, consider using an agent with little or no CYP2C19-inhibitory activity;186 187 224 230 253 350 alternatively, consider using a histamine H2-receptor antagonist (ranitidine, famotidine, nizatidine)186 187 230 but not cimetidine (also a potent CYP2C19 inhibitor)232 233
See table entry for gastric pH-dependent drugs
Diuretics (i.e., loop or thiazide diuretics)
Possible increased risk of hypomagnesemia327
Use of esomeprazole with fosamprenavir (with or without ritonavir) did not substantially affect concentrations of amprenavir (active metabolite of fosamprenavir)345
Gastric pH-dependent drugs (e.g., ampicillin esters, digoxin, iron salts, ketoconazole)
No dosage adjustment required when proton-pump inhibitors used with lopinavir/ritonavir179
Manufacturer of lansoprazole recommends considering temporary discontinuance of proton-pump inhibitor therapy in some patients receiving high-dose methotrexate1
Some clinicians recommend withholding the proton-pump inhibitor for several days before and after administration of either high-dose or low-dose methotrexate or, alternatively, substituting a histamine H2-receptor antagonist for the proton-pump inhibitor333 334
Possible increased concentrations of tacrolimus, particularly in transplant patients who are intermediate or poor metabolizers of CYP2C19 substrates1
Prolonged binding to gastric parietal proton pump enzyme.1
Plasma Protein Binding
In parietal cell secretory canaliculi, thought to be transformed into 2 active sulfenamide metabolites not present in systemic circulation.1 2 4 9 19 33 134 Also metabolized in the liver by CYP3A and CYP2C19.1 134 189 190 Metabolites found in plasma are inactive.1 134
Lansoprazole is a racemic mixture of R- and S-isomers.188 189 Plasma clearance of the R-isomer (dexlansoprazole) is slower than that of the S-isomer; plasma concentrations of the R-isomer are markedly higher than those of the S-isomer.188 189
Capsules and Orally Disintegrating Tablets
25°C (may be exposed to 15–30°C).1
Capsules for Self-medication
20–25°C; protect from high heat, humidity, and moisture.191
For information on systemic interactions resulting from concomitant use, see Interactions.
Immediately use extemporaneous mixtures of capsule contents and food or juice.1 (See Oral Administration under Dosage and Administration.)
Concentrates in acid conditions of parietal cell secretory canaliculi; forms active sulfenamide metabolite that irreversibly binds to and inactivates hydrogen-potassium ATPase (proton or acid pump), blocking final step in secretion of hydrochloric acid.1 2 4 9 18 19 33
Advice to Patients
For orally disintegrating tablets, importance of allowing tablet to dissolve on tongue with or without water, then swallowing particles without chewing.1
If capsule contents are mixed with food or juice, importance of immediately swallowing mixture without crushing or chewing.1
Risk of hypomagnesemia; importance of immediately reporting and seeking care for any cardiovascular or neurologic manifestations (e.g., palpitations, dizziness, seizures, tetany).1
Importance of informing patients with phenylketonuria that orally disintegrating tablets contain aspartame.1
Possible increased risk of Clostridium difficile infection; importance of contacting a clinician if persistent watery stools, abdominal pain, and fever occur.335
Importance of following dosage instructions when lansoprazole is used for self-medication.191 Advise patients that they should use the drug for self-medication only as directed for no longer than 14 days of continuous use and that they should not exceed one course of therapy every 4 months.305
Importance of discontinuing use as self-medication and consulting a clinician if heartburn persists or worsens, use of the drug for >14 days is needed, or >1 course of therapy is required every 4 months.191
Self-medication with lansoprazole is not intended for immediate relief of heartburn; may relieve symptoms within 24 hours, but 1–4 days may be required for complete relief.191
Advise patients to consult their clinician before using lansoprazole for self-medication if they have liver disease, have had heartburn for >3 months, or are experiencing heartburn with lightheadedness, dizziness, or sweating; chest or shoulder pain with shortness of breath, sweating, lightheadedness, or pain spreading to the arms, neck, or shoulders; frequent chest pain; frequent wheezing (especially with heartburn); unexplained weight loss; nausea or vomiting; or stomach pain.191
Advise patients not to use lansoprazole for self-medication and to consult a clinician if they have difficulty or pain with swallowing, are vomiting blood, or have bloody or blackened stools.191
Excipients in commercially available drug preparations may have clinically important effects in some individuals; consult specific product labeling for details.
* available from one or more manufacturer, distributor, and/or repackager by generic (nonproprietary) name
Capsules, delayed-release (containing enteric-coated granules)
Lansoprazole Delayed-Release Capsules
Lansoprazole Delayed-Release Capsules
Tablets, delayed-release (containing enteric-coated microgranules), orally disintegrating
4 Capsules, Amoxicillin (trihydrate) 500 mg (of amoxicillin)
2 Capsules, delayed-release (containing enteric-coated granules), Lansoprazole, 30 mg (Prevacid)
2 Tablets, film-coated, Clarithromycin, 500 mg (Biaxin Filmtab)
This pricing information is subject to change at the sole discretion of DS Pharmacy. This pricing information was updated 02/2014. Actual costs to patients will vary depending on the use of specific retail or mail-order locations and health insurance copays.
Amoxicillin 250MG Capsules (TEVA PHARMACEUTICALS USA): 90/$17.99 or 180/$25.97
Amoxicillin 500MG Capsules (SANDOZ): 30/$15.99 or 60/$20.97
Biaxin 250MG Tablets (ABBOTT): 60/$361.00 or 180/$1,025.97
Biaxin 500MG Tablets (ABBOTT): 20/$129.98 or 60/$369.98
Clarithromycin 250MG Tablets (SANDOZ): 30/$148.99 or 90/$426.99
Clarithromycin 500MG Tablets (TEVA PHARMACEUTICALS USA): 30/$125.99 or 90/$355.96
Lansoprazole 15MG Delayed-release Capsules (SANDOZ): 30/$105.99 or 90/$263.97
Lansoprazole 15MG Dispersible Tablets (SANDOZ): 30/$162.98 or 90/$466.95
Lansoprazole 30MG Delayed-release Capsules (SANDOZ): 30/$99.99 or 90/$245.97
Lansoprazole 30MG Dispersible Tablets (SANDOZ): 30/$162.98 or 90/$466.95
Prevacid 15MG Delayed-release Capsules (TAKEDA PHARMACEUTICALS): 30/$213.98 or 90/$617.99
Prevacid SoluTab 15MG Dispersible Tablets (TAKEDA PHARMACEUTICALS): 100/$631.98 or 300/$1,850.93
Prevacid SoluTab 30MG Dispersible Tablets (TAKEDA PHARMACEUTICALS): 30/$198.99 or 90/$567.94
AHFS DI Essentials. © Copyright, 2004-2015, Selected Revisions January 31, 2013. American Society of Health-System Pharmacists, Inc., 7272 Wisconsin Avenue, Bethesda, Maryland 20814.
1. Takeda Pharmaceuticals America, Inc. Prevacid (lansoprazole) delayed-release capsules and delayed-release oral disintegrating tablets prescribing information. Deerfield, IL; 2012 May.
2. Barradell LB, Faulds D, McTavish D. Lansoprazole: a review of its pharmacodynamic and pharmacokinetic properties and its therapeutic efficacy in acid-related disorders. Drugs. 1992; 44:225-50. [PubMed 1382017]
3. Spencer CM, Faulds D. Lansoprazole: a reappraisal of its pharmacodynamic and pharmacokinetic properties, and its therapeutic efficacy in acid-related disorders. Drugs. 1994; 48:403-30.
4. Landes BD, Petite JP, Flouvat B. Clinical pharmacokinetics of lansoprazole. Clin Pharmacokinet. 1995; 28:458-70. [PubMed 7656504]
5. Anon. Lansoprazole. Med Lett Drugs Ther. 1995; 37:63. [PubMed 7603391]
6. Anon. Update on proton-pump inhibitors. Intl Pharm J. 1994; 8:193-5.
7. Tap Pharmaceuticals, Inc. Product information form for American hospital formulary service: Prevacid (lansoprazole) delayed-release capsules. Deerfield, IL; 1995 May 10.
8. Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Bailliere’s Clin Gastroenterol. 1993; 7:23-54.
9. Sachs G, Shin JM, Besancon M et al. The continuing development of gastric acid pump inhibitors. Altern Pharmacol Ther. 1993; 7(Suppl 1):4-12.
10. Nagata K, Takagi E, Tsuda M et al. Inhibitory action of lansoprazole and its analogs against helicobacter pylori: inhibition of growth is not related to inhibition of urease. Antimicrob Agents Chemother. 1995; 39:567-70. [PubMed 7726537]
11. Verdü EF, Fraser R, Armstrong D et al. Effects of omeprazole and lansoprazole on 24-hour intragastric pH in helicobacter pylori-positive volunteers. Scand J Gastroenterol. 1994; 29:1065-9. [IDIS 340486] [PubMed 7886393]
12. Lanza F, Goff J, Scowcroft C et al. Double-blind comparison of lansoprazole, ranitidine, and placebo in the treatment of acute duodenal ulcer. Am J Gastroenterol. 1994; 89:1191-200. [IDIS 333819] [PubMed 8053433]
13. Hawkey CJ, Long RG, Bardham KD et al. Improved symptom relief and duodenal ulcer healing with lansoprazole, a new proton pump inhibitor, compared with ranitidine. Gut. 1993; 34:1458-62. [IDIS 320656] [PubMed 8244121]
14. Ekstrom P, Carling L, Unge P et al. Lansoprazole versus omeprazole in active duodenal ulcer. Scand J Gastroenterol. 1995; 30:210-5. [IDIS 344845] [PubMed 7770708]
15. Hongo M, Ohara S, Hirasawa Y et al. Effect of lansoprazole on intragastric pH: comparison between morning and evening dosing. Dig Dis Sci. 1992; 37:882-90. [IDIS 297692] [PubMed 1534047]
16. De Korwin JD, Joubert M, Bazin N et al. Lansoprazole versus lansoprazole plus antibiotics in the treatment of helicobacter pylori gastric infection. Gastroenterology. 1991; 100(Suppl):A67.
17. Mauch F, Bode G, Malfertheiner P. Identification and characterization of an ATPase system of Helicobacter pylori and the effect of proton pump inhibitors. Am J Gastroenterol. 1993; 88:1801-2. [IDIS 321168] [PubMed 8213737]
18. Robinson M, Sahba B, Avner D et al. A comparison of lansoprazole and ranitidine in the treatment of erosive oesophagitis. Aliment Pharmacol Ther. 1995; 9:25-31. [PubMed 7766740]
19. Robinson M, Campbell DR, Sontag S et al. Treatment of erosive reflux esophagitis resistant to H2-receptor antagonist therapy. Dig Dis Sci. 1995; 40:590-7. [IDIS 344492] [PubMed 7895551]
20. Feldman M, Harford WV, Fisher RS et al. Treatment of reflux esophagitis resistant to H2-receptor antagonists with lansoprazole, a new H+K+-ATPase inhibitor: a controlled, double-blind study. Am J Gastroenterol. 1993; 88:1212-7. [IDIS 318336] [PubMed 8101695]
21. Hatlebank JG, Berstad A, Carling L et al. Lansoprazole versus omeprazole in short-term treatment of reflux oesophagitis. Scan J Gastroenterol. 1993; 28:224-8.
22. Berstad A, Hatlebakk JG. Lansoprazole in the treatment of reflux oesophagitis: a survey of clinical studies. Aliment Pharmacol Ther. 1993; 7(Suppl 1):34-6. [PubMed 8490077]
23. Howden CW, Castell dO, Cohen S et al. The rationale for continuous maintenance treatment of reflux esophagitis. Arch Intern Med. 1995; 155:1465-71. [IDIS 351325] [PubMed 7605147]
24. Jensen RT, Metz DC, Koviack PD et al. Prospective study of the long-term efficacy and safety of lansoprazole in patients with the Zollinger-Ellison syndrome. Ailment Pharmacol Ther. 1993; 7(Suppl 1):41-50.
25. Metz DC, Pisegna JR, Ringham GL et al. Prospective study of efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig Dis Sci. 1993; 38:245-56. [IDIS 309699] [PubMed 8425437]
26. Jensen RT, Fraker DL. Zollinger-Ellison syndrome: advances in treatment of gastric hypersecretion and the gastrinoma. JAMA. 1994; 271:1429-35. [IDIS 329237] [PubMed 7513768]
27. Metz DC, Pisegna JR, Fishbeyn VA et al. Control of gastric acid hypersecretion in the management of patients with Zollinger-Ellison syndrome. World J Surg. 1993; 17:468-80. [PubMed 8362529]
28. Hirschowitz BJ, Hohnen J, Shaw S. Zollinger-Ellison syndrome treated with lansoprazole. Gastroenterolog. 1993; 104:A100.
29. Cavanaugh JH, Winters EP, Cohen A et al. Lack of effect of lansoprazole on steady state warfarin metabolism. Gastroenterology. 1991; 100:A40.
30. Granneman g, Winters EP, Locke CS et al. Lack of effect of concomitant lansoprazole on steady-state theophylline pharmacokinetics. Gastroenterology. 1991; 100:A75.
31. Cavanaugh JH, Schneck DW, Mukherji D et al. Lack of effect of concomitant lansoprazole on single-dose propranolol pharmacokinetics and pharmacodynamics. Gastroenterology. 1994; 106:A4.
32. Mukherji D, Cavanaugh JH. Lack of effect of concomitant multi-dose lansoprazole on single-dose phenytoin pharmacokinetics in subjects. Gastroenterology. 1994; 106:A103.
33. Hussein Z, Granneman GR, Mukherjee D et al. Age-related differences in the pharmacokinetics and pharmacodynamics of lansoprazole. Br J Clin Pharmacol. 1993; 36:391-8. [PubMed 12959285]
34. Flouvat B, Delhotal-Landes B, Cournot A et al. Single and multiple dose pharmacokinetics of lansoprazole in elderly subjects. Br J Clin Pharmacol. 1993; 36:467-9. [PubMed 12959297]
35. Lefebvre RA, Flouvat B, Karola-Tamisier S et al. Influence of lansoprazole treatment on diazepam plasma concentrations. Clin Pharmacol Ther. 1992; 52:458-63. [IDIS 306300] [PubMed 1424419]
36. Delhotal-Landes B, Flouvat B, Duchier J et al. Pharmacokinetics of lansoprazole in patients with renal or liver disease of varying severity. Eur J Clin Pharmacol. 1993; 45:367-71. [IDIS 323307] [PubMed 8299672]
37. Shamburek RD, Schubert ML. Pharmacology of gastric acid inhibition. Bailliére’s Clin Gastroenterol. 1993; 7:23-54.
38. Cerulli MA, Cloud ML, Offen WW et al. Nizatidine as maintenance therapy of duodenal ulcer disease in remission. Scand J Gastroenterol. 1987; 22(Suppl 136):79-83.
39. Hentschel E, Schütze K, Reichel W et al. Nizatidine versus ranitidine in the prevention of duodenal ulcer relapse: six-month interim results of a European multicentre study. Scand J Gastroenterol. 1987; 22(Suppl 136):84-8.
40. Chun AHC, Eason CJ, Shi HH et al. Lansoprazole: an alternative method of administration of a capsule dosage formulation. Clin Ther. 1995; 17:441-7. [IDIS 350575] [PubMed 7585848]
41. Eissele R, Brunner G, Fischer B et al. Evaluation of enterochromaffin-like (ECL)-cell hyperplasia during long-term treatment with the proton pump inhibitor lansoprazole. Gastroenterology. 1993; 104:A74.
42. Rodrigues AD, Freston JW. PPI effects on the cytochrome P450system: implications to significant drug interactions. In: Giuli R, ed. The esophageal mucosa, 300 questions – 300 answers. Amsterdam: Elsevier Science; 1994:460-4.
43. Tap Pharmaceuticals, Inc., Deerfield, IL: Personal communication.
44. Ateshkadi A, Lam NP, Johnson CA. Helicobacter pylori and peptic ulcer disease. Clin Pharm. 1993; 12:34-48. [IDIS 307044] [PubMed 8428432]
45. Blaser MJ. Helicobacter pylori: its role in disease. Clin Infect. 1992; 15:386-91.
46. Marshall BJ. Treatment strategies for Helicobacter pylori infection. Gastroenterol Clin North Am. 1993; 22:183-98. [PubMed 8449566]
47. Israel DM, Hassall E. Treatment and long-term follow-up of Helicobacter pylori-associated duodenal ulcer disease in children. J Pediatr. 1993; 123:53-8. [IDIS 317697] [PubMed 8320625]
48. Murray DM, DuPont HL, Cooperstock M et al. Evaluation of new anti-infective drugs for the treatment of gastritis and peptic ulcer disease associated with infection by Helicobacter pylori. Clin Infect Dis. 1992; 15(Suppl 1):S268-73.
49. Chiba N, Rao BV, Rademaker JW et al. Meta-analysis of the efficacy of antibiotic therapy in eradicating Helicobacter pylori. Am J Gastroenterol. 1992; 87:1716-27. [IDIS 307322] [PubMed 1449132]
50. Glassman MS. Helicobacter pylori infection in children. A clinical overview. Clin Pediatr (Phila). 1992; 31:481-7. [IDIS 300639] [PubMed 1643767]
51. Peterson WL. Helicobacter pylori and peptic ulcer disease. N Engl J Med. 1991; 324:1043-8. [IDIS 279263] [PubMed 2005942]
52. Logan RP, Gummett PA, Misiewicz JJ et al. One week eradication regimen for Helicobacter pylori. Lancet. 1991; 338:1249-52. [IDIS 288032] [PubMed 1682653]
53. Burette A, Glupczynski Y. On: The who’s and when’s of therapy for Helicobacter pylori. 1991; 86:924-5. Letter.
54. Bayerdorffer E, Mannes GA, Sommer A et al. Long-term follow-up after eradication of Helicobacter pylori with a combination of omeprazole and amoxycillin. Scand J Gastroenterol Suppl. 1993; 196:19-25. [PubMed 8341987]
55. Unge P, Ekstrom P. Effects of combination therapy with omeprazole and an antibiotic on H. pylori and duodenal ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:17-8.
56. Hunt RH. Hp and pH: implications for the eradication of Helicobacter pylori. Scand J Gastroenterol Suppl. 1993; 196:12-6. [PubMed 8341986]
57. Malfertheiner P. Compliance, adverse events and antibiotic resistance in Helicobacter pylori treatment. Scand J Gastroenterol Suppl. 1993; 196:34-7. [PubMed 8341989]
58. Bell GD, Powell U. Eradication of Helicobacter pylori and its effect in peptic ulcer disease. Scand J Gastroenterol Suppl. 1993; 196:7-11. [PubMed 8341990]
59. Adamek RJ, Wegener M, Opferkuch W et al. Successful Helicobacter pylori eradication: a systemic effect of antibiotics? Am J Gastroenterol. 1993; 88:792-3. Letter.
60. Bianchi Porro G, Parente F, Lazzaroni M. Short and long term outcome of Helicobacter pylori positive resistant duodenal ulcers treated with colloidal bismuth subcitrate plus antibiotics or sucralfate alone. Gut. 1993; 34:466-9. [IDIS 312865] [PubMed 8491391]
61. Graham DY, Go MF. Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated. Clin Infect Dis. 1993; 17:293-4. [PubMed 8399892]
62. Murray DM, DuPont HL. Reply. (Evaluation of new antiinfective drugs for Helicobacter pylori infection: revisited and updated.) Clin Infect Dis. 1993; 17:294-5.
63. George LL, Borody TJ, Andrews P et al. Cure of duodenal ulcer after eradication of H. pylori. Med J Aust. 1990; 153:145-9. [IDIS 273364] [PubMed 1974027]
64. Farrell MK. Dr. Apley meets Helicobacter pylori. J Pediatr Gastroenterol Nutr. 1993; 16:118-9. [PubMed 8450375]
65. Fiocca R, Solcia E, Santoro B. Duodenal ulcer relapse after eradication of Helicobacter pylori. Lancet. 1991; 337:1614. [PubMed 1675746]
66. Marshall BJ. Campylobacter pylori: its link to gastritis and peptic ulcer disease. Clin Infect Dis. 1990; 12(Suppl 1):S87-93.
67. Nomura A, Stemmermann GN, Chyou PH et al. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991; 325:1132-6. [PubMed 1891021]
68. Parsonnet J, Friedman GD, Vandersteen DP et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325:1127-31. [PubMed 1891020]
69. The EUROGAST Study Group. An international association between Helicobacter pylori infection and gastric cancer. Lancet. 1993; 341:1359-62. [PubMed 8098787]
70. Talley NJ, Zinsmeister AR, Weaver A et al. Gastric adenocarcinoma and Helicobacter pylori infection. J Natl Cancer Inst. 1991; 83:1734-9. [PubMed 1770552]
71. Forman D, Newell DG, Fullerton F et al. Association between infection with Helicobacter pylori and risk of gastric cancer: evidence from a prospective investigation. BMJ. 1991; 302:1302-5. [PubMed 2059685]
72. Forman D. Helicobacter pylori infection: a novel risk factor in the etiology of gastric cancer. J Natl Cancer Inst. 1991; 83:1702-3. [PubMed 1770545]
73. Parsonnet J. Helicobacter pylori and gastric cancer. Gastroenterol Clin North Am. 1993; 22:89-104. [PubMed 8449573]
74. Correa P. Is gastric carcinoma an infectious disease? N Engl J Med. 1991; 325:1170-1.
75. Isaacson PG, Spencer J. Is gastric lymphoma an infectious disease? Hum Pathol. 1993; 24:569-70.
76. Borody T, Andrews P, Mancuso N et al. Helicobacter pylori reinfection 4 years post-eradication. Lancet. 1992; 339:1295. [PubMed 1349686]
77. Hixson LJ, Kelley CL, Jones WN et al. Current trends in the pharmacotherapy for peptic ulcer disease. Arch Intern Med. 1992; 152:726-32. [IDIS 295736] [PubMed 1558429]
78. Rauws EAJ, Tytgat GNJ. Cure of duodenal ulcer with eradication of Helicobacter pylori. Lancet. 1990; 335:1233-5. [IDIS 267578] [PubMed 1971318]
79. Hunt RH. pH and Hp—gastric acid secretion and Helicobacter pylori: implications for ulcer healing and eradication of the organism. Am J Gastroenterol. 1993; 88:481-3. [IDIS 313340] [PubMed 8470623]
80. Hentschel E, Brandstatter G, Dragosics B et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med. 1993; 328:308-12. [IDIS 308862] [PubMed 8419816]
81. Graham DY, Lew GM, Evans DG et al. Effect of triple therapy (antibiotics plus bismuth) on duodenal ulcer healing: a randomized controlled trial. Ann Intern Med. 1991; 115:266-9. [IDIS 284354] [PubMed 1854110]
82. Reviewers’ comments (personal observations) on Helicobacter pylori; 1993 Oct 26.
83. Marshall BJ. Helicobacter pylori. Am J Gastroenterol. 1994; 89(Suppl):S116-28.
84. Labenz J, Gyenes E, Rühl GH et al. Amoxicillin plus omeprazole versus triple therapy for eradication of Helicobacter pylori in duodenal ulcer disease: a prospective, randomized, and controlled study. Gut. 1993; 34:1167-70. [IDIS 320468] [PubMed 8406147]
85. Labenz J, Gyenes E, Rühl GH et al. Omeprazole plus amoxicillin: efficacy of various treatment regimens to eradicate Helicobacter pylori. Am J Gastroenterol. 1993; 88:491-5. [IDIS 313342] [PubMed 8470626]
86. Bell GD, Powell KU, Burridge SM et al. Helicobacter pylori eradication: efficacy and side effect profile of a combination of omeprazole, amoxycillin and metronidazole compared with four alternative regimens. Q J Med. 1993; 86:743-50. [IDIS 322332] [PubMed 8265776]
87. Labenz J, Rühl GH, Bertrams J et al. Medium- and high-dose omeprazole plus amoxicillin for eradication of Helicobacter pylori in duodenal ulcer disease. Dig Dis Sci. 1994; 39:1483-7. [IDIS 333050] [PubMed 8026260]
88. Labenz J, Börsch G. Highly significant change of the clinical course of relapsing and complicated peptic ulcer disease after cure of Helicobacter pylori infection. Am J Gastroenterol. 1994; 89: 1785-8.
89. Wang WM, Chen CY, Jan CM et al. Long-term follow-up and serological study after triple therapy of Helicobacter pylori-associated duodenal ulcer. Am J Gastroenterol. 1994; 89:1793-6. [IDIS 336723] [PubMed 7942669]
90. Savarino V, Sandro Mela G, Zentilin P et al. Acid inhibition and amoxicillin activity against Helicobacter pylori. Am J Gastroenterol. 1993; 88:1975-6. [IDIS 321725] [PubMed 8237959]
91. Labenz J, Börsch G. Acid inhibition and amoxicillin activity against Helicobacter pylori: response to Savarino et al. Am J Gastroenterol. 1993; 88:1976. [IDIS 321727] [PubMed 8292199]
92. Anon. Drugs for treatment of peptic ulcers. Med Lett Drugs Ther. 1994; 36:65-7. [PubMed 7912812]
93. Freston JW. Emerging strategies for managing peptic ulcer disease. Scand J Gastroenterol Suppl. 1994; 201:49-54. [PubMed 8047824]
94. Axon ATR. The role of acid inhibition in the treatment of Helicobacter pylori infection. Scand J Gastroenterol Suppl. 1994; 201:16-23. [PubMed 8047818]
95. Labenz J, Rühl GH, Bertrams J et al. Medium- or high-dose omeprazole plus amoxicillin eradicates Helicobacter pylori in gastric ulcer disease. Am J Gastroenterol. 1994; 89:726-30. [IDIS 329264] [PubMed 8172146]
96. Labenz J, Borsch G. Evidence for the essential role of Helicobacter pylori in gastric ulcer disease. Gut. 1994; 35:19-22. [IDIS 324883] [PubMed 8307443]
97. NIH Consensus Development Panel on Helicobacter pylori in Peptic Ulcer Disease. Helicobacter pylori in peptic ulcer disease. JAMA. 1994; 272:65-9. [IDIS 332306] [PubMed 8007082]
98. Fennerty MB. Helicobacter pylori. Ann Intern Med. 1994; 154:721-7.
99. Adamek RJ, Wegener M, Labenz J et al. Medium-term results of oral and intravenous omeprazole/amoxicillin Helicobacter pylori eradication therapy. Am J Gastroenterol. 1994; 89:39-42. [IDIS 324011] [PubMed 8273795]
100. Peura DA, Graham DY. Helicobacter pylori: consensus reached: peptic ulcer is on the way to becoming an historic disease. Am J Gastroenterol. 1994; 89:1137-9. [PubMed 8053422]
101. Cotton P. NIH consensus panel urges antimicrobials for ulcer patients, skeptics concur with caveats. JAMA. 1994; 271:808-9. [PubMed 8114221]
102. Feldman M. The acid test. Making clinical sense of the consensus conference on Helicobacter pylori. JAMA. 1994; 272:70-1. [PubMed 8007084]
103. Harris AW, Gummett PA, Logan RPH et al. Eradication of Helicobacter pylori with lansoprazole and clarithromycin. Aliment Pharmacol Ther. 1995; 9:201-4. [PubMed 7605863]
104. Lamouliatte H. Effect of lansoprazole on Helicobacter pylori. Clin Ther. 1993; 15(Suppl B):32-6. [PubMed 8205593]
105. Sloane R, Cohen H. Common-sense management of Helicobacter pylori-associated gastroduodenal disease. Personal views. Gastroenterol Clin North Am. 1993; 22:199-206. [PubMed 8449567]
106. Abbott Laboratories. Biaxin (clarithromycin) Filmtab tablets and granules for oral suspension prescribing information. Abbott Park, IL; 1996 Apr.
107. Markham A, McTavish D. Clarithromycin and omeprazole: as Helicobacter pylori eradication therapy in patients with H. pylori-associated gastric disorders. Drugs. 1996; 51:161-78. [PubMed 8741237]
108. Sung JJY, Chung SCS, Ling TKW et al. Dual therapy versus triple therapy for Helicobacter pylori-associated duodenal ulcers. Dig Dis Sci. 1996; 41:453-7. [IDIS 365161] [PubMed 8617114]
109. Soll AH. Medical treatment of peptic ulcer disease. JAMA. 1996; 275:622-9. [IDIS 361115] [PubMed 8594244]
110. Soll AH. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1136-7.
111. Reviewers’ comments (personal observations) on the Aminopenicillins General Statement 8:12.16.
112. Walsh JH, Peterson WL. The treatment of Helicobacter pylori infection in the management of peptic ulcer disease. N Engl J Med. 1995; 333:984-91. [IDIS 354448] [PubMed 7666920]
113. Hackelsberger A, Malfertheiner P. A risk-benefit assessment of drugs used in the eradication of Helicobacter pylori infection. Drug Saf. 1996; 15:30-52. [PubMed 8862962]
114. Rauws EAJ, van der Hulst RWM. Current guidelines for the eradication of Helicobacter pylori in peptic ulcer disease. Drugs. 1995; 6:984-90.
115. van der Hulst RWM, Keller JJ, Rauws EAJ et al. Treatment of Helicobacter pylori infection: a review of the world literature. Helicobacter. 1996; 1:6-19. [PubMed 9398908]
116. Lind T, Veldhuyzen van Zanten S, Unge P et al. Eradication of Helicobacter pylori using one-week triple therapies combining omeprazole with two antimicrobials: the MACH I study. Helicobacter. 1996; 1:138-44. [PubMed 9398894]
117. Anon. The choice of antibacterial drugs. Med Lett Drugs Ther. 1996; 38:25-34. [PubMed 8598824]
118. Graham DY, Lew GM, Klein PD et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med. 1992; 116:705-8. [IDIS 295138] [PubMed 1558340]
119. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol. 1993; 88:505-9. [IDIS 313343] [PubMed 8470629]
120. Logan RP, Gummett PA, Hegarty BT et al. Clarithromycin and omeprazole for Helicobacter pylori. Lancet. 1992; 25:340:239.
121. Graham DY. Treatment of peptic ulcers caused by Helicobacter pylori. N Engl J Med. 1993; 328:349-50. [IDIS 308865] [PubMed 8419823]
122. Hosking SW, Ling TK, Yung MY et al. Randomised controlled trial of short term treatment to eradicate Helicobacter pylori in patients with duodenal ulcer. BMJ. 1992; 305:502-4. [IDIS 301416] [PubMed 1392995]
123. Bell GD, Powell K, Burridge SM et al. Experience with ’triple’ anti-Helicobacter pylori eradication therapy: side effects and the importance of testing the pre-treatment bacterial isolate for metronidazole resistance. Aliment Pharmacol Ther. 1992; 6:427-35. [PubMed 1420735]
124. Fennerty MB. Practice guidelines for treatment of peptic ulcer disease. JAMA. 1996; 276:1135. [IDIS 373209] [PubMed 8827957]
125. Lindberg P, Brandstrom A, Wallmark B et al. Omeprazole: the first proton pump inhibitor. Medicinal Res Rev. 1990; 10:1-54.
126. Langtry HD, Wilde IW. Lansoprazole: an update of its pharmacological properties and clinical efficacy in the management of acid-related disorders. Drugs. 1997; 54:1473-500.
127. Chun AHC, Shi HH, Achari R et al. Lansoprazole: administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther. 1996; 18:833-42. [IDIS 376627] [PubMed 8930427]
128. Greco S, Mazzaglia G. Glossitis, stomatitis, and black tongue with lansoprazole plus clarithromycin. Ann Pharmacother. 1995; 31:1548.
129. Garnett RG. Lansoprazole: a proton pump inhibitor. Ann Pharmacother. 1996; 30:1425. [IDIS 376983] [PubMed 8968456]
130. Unge P, Anderson T. Drug interactions with proton pump inhibitors. Drugs. 1997; 3:171-9.
131. Zimmerman AE, Katona BG. Lansoprazole: a comprehensive review. Pharmacother. 1997; 17:308-26.
132. Hatlebakk JG, Nesje LB, Hausken T et al. Lansoprazole capsules and amoxicillin oral suspension in the treatment of peptic ulcer disease. Scand J Gastroenterol. 1995; 11:1053-7.
133. Leufkens H, Claessens A, Heerdink E et al. A prospective follow-up study of 5669 users of lansoprazole in daily practice. Aliment Pharmacol Ther. 1997; 11:887-97. [PubMed 9354197]
134. Takeda Pharmaceuticals America, Inc. PrevPac (lansoprazole 30-mg capsules, amoxicillin 500-mg capsules, and clarithromycin 500-mg tablets) prescribing information. Deerfield, IL; 2009 Oct.
135. Salcedo JA, Al-Kawas F. Treatment of Helicobacter pylori infection. Arch Intern Med. 1998; 158:842-51. [IDIS 405335] [PubMed 9570169]
136. Roth S, Agrawal N, Mahowald M et al. Misoprostol heals gastroduodenal injury in patients with rheumatoid arthritis receiving aspirin. Arch Intern Med. 1989; 149:775-9. [IDIS 253955] [PubMed 2495779]
137. Nightingale S. Warning changes on NSAIA labeling. JAMA. 1989; 261:1396.
138. Graham DY. Prevention of gastroduodenal injury induced by chronic nonsteroidal antiinflammatory drug therapy. Gastroenterology. 1989; 96:675-81. [IDIS 250827] [PubMed 2642452]
139. Knodel LC. Preventing NSAID-induced gastric ulcers: the role of misoprostol. Hosp Formul. 1989; 24(Suppl A):27-30.
140. Stern WR. Summary of the 33rd meeting of the Food and Drug Administration’s Gastrointestinal Drugs Advisory Committee, September 15-16, 1988. Am J Gastroenterol. 1989; 84:351-3. [IDIS 253713] [PubMed 2494882]
141. Miller SR, Fries JF, Spitz P et al. Patients at high risk for developing upper gastrointestinal complications associated with non-steroidal antiinflammatory drugs. Am J Gastroenterol. 1988; 83:1055.
142. Palmer JF. Letter sent to Bathish J, of Wyeth-Ayerst Laboratories regarding labeling revisions about gastrointestinal adverse reactions to Orudis (ketoprofen). Rockville, MD: Food and Drug Administration, Division of Oncology and Radiopharmaceutical Drug Products; 1988 Sep.
143. Food and Drug Administration. Labeling revisions for NSAIDs. FDA Drug Bull. 1989; 19:3-4.
144. Roth SH. Nonsteroidal anti-inflammatory drugs: gastropathy, deaths, and medical practice. Ann Intern Med. 1988; 109:353-4. [IDIS 245853] [PubMed 3044208]
145. Griffin MR, Ray WA, Schaffner W. Nonsteroidal anti-inflammatory drug use and death from peptic ulcer in elderly persons. Ann Intern Med. 1988; 109:359-63. [IDIS 245854] [PubMed 3261560]
146. Anon. Drugs for rheumatoid arthritis. Med Lett Drugs Ther. 2000; 42:57-64. [PubMed 10887424]
147. Clinch D, Banerjee AK, Ostick G et al. Non-steroidal anti-inflammatory drugs and gastrointestinal adverse effects. J R Coll Phys London. 1983; 17:228-30.
148. Levy M. Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. N Engl J Med. 1974; 290:1158-62. [PubMed 4545100]
149. Merck. Vioxx (rofecoxib) tablets and oral suspension prescribing information. West Point, PA; 1999 Sep.
150. Wolfe MM, Lichtenstein DR, Singh G. Gastrointestinal toxicity of nonsteroidal antiinflammatory drugs. N Engl J Med. 1999; 340:1888-99. [IDIS 426864] [PubMed 10369853]
151. Lanza FL and the members of the Ad Hoc Committee on Practice Parameters of the American College of Gastroenterology. A guideline for the treatment and prevention of NSAID-induced ulcers. Am J Gastroenterol. 1998; 93:2037-46. [IDIS 417402] [PubMed 9820370]
152. American College of Rheumatology Subcommittee on Rheumatoid Arthritis Guidelines. Guidelines for the management of rheumatoid arthritis. 2002 update. Arth Rheuma. 2002; 46:328-46.
153. Schoenfeld P, Kimmey MB, Scheiman J et al. Review article: nonsteroidal anti-inflammatory drug-associated gastrointestinal complications—guidelines for prevention and treatment. Aliment Pharmacol Ther. 1999; 13:1273-85. [PubMed 10540041]
154. Hawkins C, Hanks GW. The gastroduodenal toxicity of nonsteroidal anti-inflammatory drugs. A review of the literature. J Pain Symptom Manage. 2000; 20:140-51. [IDIS 453837] [PubMed 10989252]
155. Rostom A, Wells G, Tugwell P et al. The prevention of chronic NSAID induced upper gastrointestinal toxicity: A Cochrane collaboration metaanalysis of randomized controlled trials. J Rheumatol. 2000; 27:2203-14. [IDIS 452429] [PubMed 10990235]
156. DeVault KR, Castell DO, Practice Parameters Committee of the American College of Gastroenterology. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Am J Gastroenterol. 1999; 94:1434-42. [IDIS 429620] [PubMed 10364004]
157. Banks S, Greenberg R. Alternate day omeprazole in H2 receptor-antagonist resistant reflux esophagitis. Gastroenterology. 1991; 100:A29. [PubMed 2001800]
158. Dent J, Yeomans ND, Mackinnon M et al. Omeprazole v ranitidine for prevention of relapse in reflux esophagitis. A controlled double blind trial of their efficacy and safety. Gut. 1994; 35:590-8. [IDIS 330781] [PubMed 8200548]
159. Sandmark S, Carlsson R, Fausa O et al. Omeprazole or ranitidine in the short-term treatment of ulcerative reflux esophagitis. Results of a double-blind randomized Scandinavian multicenter study. Scand J Gastroenterol. 1988; 23:625-32. [IDIS 252240] [PubMed 3041558]
160. Chan FKL, Hung LCT, Suen BY et al. Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med. 2002; 347:2104-10. [IDIS 490812] [PubMed 12501222]
161. Graham DY. NSAIDs, Helicobacter pylori, and Pandora’s box. N Engl J Med. 2002; 347:2162-4. [IDIS 490815] [PubMed 12501230]
162. Hanauer SB, Sandborn W, and the Practice Parameters Committee of the American College of Gastroenterology. Management of Crohn’s disease in adults: Practice Guidelines. Am J Gastroenterol. 2001; 96:635-43. [IDIS 461432] [PubMed 11280528]
163. Valori RM, Cockel R. Omeprazole for duodenal ulceration in Crohn’s disease. Br Med J. 1990; 300:438-9.
164. Bianchi G, Ardizzone S, Petrillo M et al. Omeprazole for peptic ulcer in Crohn’s disease. Am J Gastroenterol. 1991; 86: 245-6. [PubMed 1992643]
165. Przemioslo RT, Mee AS. Omeprazole in possible esophageal Crohn’s disease. Dig Dis Sci. 1994; 39:1594-5. [IDIS 333053] [PubMed 8026276]
166. Dickinson JB. Is omeprazole helpful in inflammatory bowel disease? J Clin Gastroenterol. 1994; 18:317-9.
167. Abrahao LJ Jr., Abrahao LJ, Vargas C et al. [Gastoduodenal Crohn’s disease—report of 4 cases and review of the literature]. (Portuguese; with English abstract.) Arq Gastroenterol. 2001; 38:57-62.
168. Freston JW. Review article: role of proton pump inhibitors in non-H. pylori-related ulcers. Aliment Pharmacol Ther. 2001; 15: (Suppl 2)2-5. [PubMed 11556873]
169. Graham DY, Agrawal NM, Campbell DR et al. Ulcer prevention in long-term users of nonsteroidal anti-inflammatory drugs: results of a double-blind, randomized, multicenter, active- and placebo-controlled study of misoprostol vs lansoprazole. Arch Intern Med. 2002; 162:169-75. [IDIS 475360] [PubMed 11802750]
170. Takeda Pharmaceuticals America, Inc. Prevacid I.V. (lansoprazole) for injection prescribing information. Deerfield, IL; 2008 Jul.
171. Takeda Pharmaceuticals America, Inc. Prevacid Naprapac 500 (lansoprazole delayed-release capsules and naproxen tablets) kit prescribing information. Deerfield, IL; 2009 Feb.
172. American Medical Association Council on Scientific Affairs. Aspartame: review of safety issues. JAMA. 1985; 254:400-2.
173. Gossel TA. A review of aspartame: characteristics, safety and uses. US Pharm. 1984; 9:26,28-30.
174. Food and Drug Administration. Aspartame as an inactive ingredient in human drug products; labeling requirements. Proposed rule. [21 CFR Part 201] Fed Regist. 1983; 48:54993-5. (lDIS 178728)
175. Food and Drug Administration. Food additives permitted for direct addition to food for human consumption; aspartame. Final rule. [21 CFR Part 172] Fed Regist. 1983; 48:31376-82. (IDIS 172957)
176. Laheij RJF, Sturkenboom MCJM, Hassing RJ et al. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA. 2004;292:1955-60.
177. Gregor JC. Acid suppression and pneumonia.; a clinical indication for rational prescibing. JAMA. 2004;292:2012-3. Editorial.
178. Yang Y-X, Lewis JD, Epstein S et al. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA. 2006; 296:2947-53. [PubMed 17190895]
179. Department of Health and Human Services (DHHS) Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents (Mar 29, 2012). From the US Department of Health and Human Services HIV/AIDS Information Services (AIDSinfo) website.
180. Bristol-Myers Squibb. Reyataz (atazanavir sulfate) capsules prescribing information. Princeton, NJ; 2012 Mar.
181. Baxter Healthcare Corporation. 5% Dextrose injection, USP in MINI-BAG Plus container prescribing information. Deerfield, IL; 1995.
182. Gilard M, Arnaud B, Cornily JC et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin. JACC. 2008; 51:256-60, doi:10.1016/j.jacc.2007.06.064. Accessed 2008 Dec 8. Available from website. [PubMed 18206732]
183. Pezalla E, Day D, Pulliadath I. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JACC. 2008; 52:1038-9. Letter. [PubMed 18786491]
184. MEDCO. New study: A common class of GI medications reduce protection against heart attack in patients taking widely prescribed cardiovascular drug. Franklin Lakes, NJ; 2008 Nov 11. Press release from website.
185. Gilard M, Cornily JC, Boschat J. Initial assessment of clinical impact of a drug interaction between clopidogrel and proton pump inhibitors. JACC. 2008; 52:1039. Reply.
186. . PPI interactions with clopidogrel revisited. Med Lett Drugs Ther. 2009; 51:13-4.
187. Juurlink DN, Gomes T, Ko DT et al. A population-based study of the drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:713-8. [PubMed 19176635]
188. Vakily M, Zhang W, Wu J et al. Pharmacokinetics and pharmacodynamics of a known active PPI with a novel Dual Delayed Release technology, dexlansoprazole MR: a combined analysis of randomized controlled clinical trials *. Curr Med Res Opin. 2009; 25:627-38. [PubMed 19232037]
189. Miura M, Tada H, Yasui-Furukori N et al. Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes. Eur J Clin Pharmacol. 2004; 60:623-8. [PubMed 15448955]
190. Welage LS. Pharmacologic properties of proton pump inhibitors. Pharmacotherapy. 2003; 23:74S-80S. [PubMed 14587961]
191. Novartis. Prevacid 24HR (lansoprazole) drug facts. 2012. From prevacid24hr website. Accessed 2012 Jul 12.
192. Kushner PR, Snoddy AM, Gilderman L et al. Lansoprazole 15 mg once daily for 14 days is effective for treatment of frequent heartburn: results of 2 randomized, placebo-controlled, double-blind studies. Postgrad Med. 2009; 121:67-75. [PubMed 19641272]
193. Food and Drug Administration. Center for Drug Evaluation and Research: Application Number: 22-327, Summary review for lansoprazole (Prevacid 24 HR). From FDA website. Accessed 2009 Nov 4.
194. Peura DA, Riff DS, Snoddy AM et al. Clinical trial: lansoprazole 15 or 30 mg once daily vs. placebo for treatment of frequent nighttime heartburn in self-treating subjects. Aliment Pharmacol Ther. 2009; 30:459-68. [PubMed 19523177]
195. Takeda Pharmaceuticals America, Inc. Deerfield, IL: Personal communication.
224. Sanofi-Aventis/Bristol-Myers Squibb. Plavix, (clopidogrel bisulfate) tablets prescribing information. New York, NY; 2011 Dec.
225. Food and Drug Administration. Early communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix). Rockville, MD; 2009 Jan 26. From FDA website.
226. Siller-Matula JM, Spiel AO, Lang IM et al. Effects of pantoprazole and esomeprazole on platelet inhibition by clopidogrel. Am Heart J. 2009; 157:148.e1-5.
227. Gilard M, Arnaud B, Le Gal G et al. Influence of omeprazole on the antiplatelet action of clopidogrel associated to aspirin. J Thromb Haemost. 2006; 4:2508-9. [PubMed 16898956]
228. Anon. PPI interactions with clopidogrel. Med Lett Drugs Ther. 2009; 51:2-3.
229. Aubert RE, Epstein RS, Teagarden JR et al. Proton pump inhibitors effect on clopidogrel effectiveness: The clopidogrel Medco outcomes study. Circulation. 2008; 118:S_815, Abstract 3998.
230. Lau WC, Gurbel PA. The drug-drug interaction between proton pump inhibitors and clopidogrel. CMAJ. 2009; 180:699-700. [PubMed 19332744]
232. Food and Drug Administration. Information for heathcare professionals: Update to the labeling of clopidogrel bisulfate (marketed as Plavix) to alert heathcare professionals about a drug interaction with omeprazole (marketed as Prilosec and Prilosec OTC). Rockville, MD; 2009 Nov 17. From FDA website.
233. Food and Drug Administration. Follow-up to the January 26, 2009 Early Communication about an ongoing safety review of clopidogrel bisulfate (marketed as Plavix) and omeprazole (marketed as Prilosec and Prilosec OTC). Rockville, MD; 2009 Nov 17. From FDA website.
235. Ho PM, Maddox TM, Wang L et al. Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA. 2009; 301:937-44. [PubMed 19258584]
236. Norgard NB, Mathews KD, Wall GC. Drug-drug interaction between clopidogrel and the proton pump inhibitors. Ann Pharmacother. 2009; 43:1266-74. [PubMed 19470853]
237. Last EJ, Sheehan AH. Review of recent evidence: potential interaction between clopidogrel and proton pump inhibitors. Am J Health Syst Pharm. 2009; 66:2117-22. [PubMed 19923312]
240. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010; 170:704-10. [PubMed 20421557]
243. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009; 120:2310-2. [PubMed 19933929]
248. Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev. 2009 Jul-Aug; 17:198-200.
250. Rude MK, Chey WD. Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?. Gastroenterology. 2009; 137:1168-71. [PubMed 19635603]
253. Food and Drug Administration. Information on clopidogrel bisulfate (marketed as Plavix). Rockville, MD; 2010 Oct 27. From FDA website.
254. AstraZeneca. Nexium (esomeprazole magnesium) delayed-release capsules and packets for delayed-release oral suspension prescribing information. Wilmington, DE; 2011 Jun.
300. Vestergaard P, Rejnmark L, Mosekilde L. Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79:76-83. [PubMed 16927047]
301. Corley DA, Kubo A, Zhao W et al. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. Gastroenterology. 2010; 139:93-101. [PubMed 20353792]
302. Yu EW, Blackwell T, Ensrud KE et al. Acid-suppressive medications and risk of bone loss and fracture in older adults. Calcif Tissue Int. 2008; 83:251-9. [PubMed 18813868]
303. Gray SL, LaCroix AZ, Larson J et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women’s Health Initiative. Arch Intern Med. 2010; 170:765-71. [PubMed 20458083]
304. Targownik LE, Lix LM, Metge CJ et al. Use of proton pump inhibitors and risk of osteoporosis-related fractures. CMAJ. 2008; 179:319-26. [PubMed 18695179]
305. Food and Drug Administration. Possible increased risk of fractures of the hip, wrist, and spine with the use of proton pump inhibitors. May 25, 2010. From FDA web site ().
307. Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010; :.
308. Targownik LE, Lix LM, Leung S et al. Proton-pump inhibitor use is not associated with osteoporosis or accelerated bone mineral density loss. Gastroenterology. 2010; 138:896-904. [PubMed 19931262]
310. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy. 2008; 28:951-9. [PubMed 18657011]
311. Abraham NS, Hlatky MA, Antman EM et al. ACCF/ACG/AHA 2010 Expert Consensus Document on the Concomitant Use of Proton Pump Inhibitors and Thienopyridines: A Focused Update of the ACCF/ACG/AHA 2008 Expert Consensus Document on Reducing the Gastrointestinal Risks of Antiplatelet Therapy and NSAID Use. A report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. JACC. 2010; 56: Published online Nov 8, 2010.
312. Last EJ, Sheehan AH. Review of recent evidence: potential interaction between clopidogrel and proton pump inhibitors. Am J Health Syst Pharm. 2009; 66:2117-22. [PubMed 19923312]
313. Stockl KM, Le L, Zakharyan A et al. Risk of rehospitalization for patients using clopidogrel with a proton pump inhibitor. Arch Intern Med. 2010; 170:704-10. [PubMed 20421557]
314. Juurlink DN. Proton pump inhibitors and clopidogrel: putting the interaction in perspective. Circulation. 2009; 120:2310-2. [PubMed 19933929]
315. Khalique SC, Cheng-Lai A. Drug interaction between clopidogrel and proton pump inhibitors. Cardiol Rev. 2009 Jul-Aug; 17:198-200.
316. Rude MK, Chey WD. Proton-pump inhibitors, clopidogrel, and cardiovascular adverse events: fact, fiction, or something in between?. Gastroenterology. 2009; 137:1168-71. [PubMed 19635603]
317. Furlanetto TW, Faulhaber GA. Hypomagnesemia and Proton Pump Inhibitors: Below the Tip of the Iceberg. Arch Intern Med. 2011; :. [PubMed 21555654]
318. Fernández-Fernández FJ, Sesma P, Caínzos-Romero T et al. Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole. Neth J Med. 2010; 68:329-30. [PubMed 21071783]
319. Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. QJM. 2010; 103:387-95. [PubMed 20378675]
320. Shabajee N, Lamb EJ, Sturgess I et al. Omeprazole and refractory hypomagnesaemia. BMJ. 2008; 337:a425. [PubMed 18617497]
321. . In brief: PPI’s and hypomagnesemia. Med Lett Drugs Ther. 2011; 53:25.
322. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008; 69:338-41. [PubMed 18221401]
323. Broeren MA, Geerdink EA, Vader HL et al. Hypomagnesemia induced by several proton-pump inhibitors. Ann Intern Med. 2009; 151:755-6. [PubMed 19920278]
324. Metz DC, Sostek MB, Ruszniewski P et al. Effects of esomeprazole on acid output in patients with Zollinger-Ellison syndrome or idiopathic gastric acid hypersecretion. Am J Gastroenterol. 2007; 102:2648-54. [PubMed 17764495]
325. Kuipers MT, Thang HD, Arntzenius AB. Hypomagnesaemia due to use of proton pump inhibitors--a review. Neth J Med. 2009; 67:169-72. [PubMed 19581665]
326. Epstein M, McGrath S, Law F. Proton-pump inhibitors and hypomagnesemic hypoparathyroidism. N Engl J Med. 2006; 355:1834-6. [PubMed 17065651]
327. US Food and Drug Administration. FDA drug safety communication: Low magnesium levels can be associated with long-term use of proton pump inhibitor drugs (PPIs). Rockville, MD; 2011 March 2. From FDA website.
328. US Food and Drug Administration. Proton pump inhibitor drugs (PPIs): Drug safety communication- Low magnesium levels can be associated with long-term use. Rockville, MD; 2011 March 2. From FDA website.
329. Hoorn EJ, van der Hoek J, de Man RA et al. A case series of proton pump inhibitor-induced hypomagnesemia. Am J Kidney Dis. 2010; 56:112-6. [PubMed 20189276]
330. Regolisti G, Cabassi A, Parenti E et al. Severe hypomagnesemia during long-term treatment with a proton pump inhibitor. Am J Kidney Dis. 2010; 56:168-74. [PubMed 20493607]
331. GlaxoSmithKline. Lanoxin (digoxin) tablets prescribing information. Research Triangle Park, NC; 2009 Aug.
333. Bezabeh S, Mackey AC, Kluetz P et al. Accumulating evidence for a drug-drug interaction between methotrexate and proton pump inhibitors. Oncologist. 2012; 17:550-4. [PubMed 22477728]
334. Horn JR, Hansten PD. Methotrexate and proton pump inhibitors. Pharm Times. 2012; 78(4). Published online 2012 Apr 9.
335. Food and Drug Administration. Drug safety communication: Clostridium difficile-associated diarrhea can be associated with stomach acid drugs known as proton pump inhibitors (PPIs). Rockville, MD; 2012 Feb 8. From FDA website. Accessed 2012 May 3l.
336. Cohen SH, Gerding DN, Johnson S et al. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol. 2010; 31:431-55. [PubMed 20307191]
337. Shah S, Lewis A, Leopold D et al. Gastric acid suppression does not promote clostridial diarrhoea in the elderly. QJM. 2000; 93:175-81. [PubMed 10751237]
338. Leonard AD, Ho KM, Flexman J. Proton pump inhibitors and diarrhoea related to Clostridium difficile infection in hospitalised patients: a case-control study. Intern Med J. 2012; 42:591-4. [PubMed 22616966]
339. Kwok CS, Arthur AK, Anibueze CI et al. Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis. Am J Gastroenterol. 2012; 107:1011-9. [PubMed 22525304]
340. Dial S, Delaney JA, Barkun AN et al. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA. 2005; 294:2989-95. [PubMed 16414946]
341. Nerandzic MM, Pultz MJ, Donskey CJ. Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection. Antimicrob Agents Chemother. 2009; 53:4133-7. [PubMed 19667292]
343. Tibotec Therapeutics. Edurant (rilpivirine) tablets prescribing information. Raritan, NJ; 2011 May.
344. Abbott Laboratories. Kaletra (lopinavir/ritonavir) oral tablets and solution prescribing information. North Chicago, IL; 2012 May.
345. ViiV Healthcare. Lexiva (fosamprenavir calcium) tablets and oral suspension prescribing information. Research Triangle Park, NC; 2012 Apr.
346. Genentech USA. Invirase (saquinavir mesylate) capsules and tablets prescribing information. South San Francisco, CA; 2012 Feb.
348. Merck Sharp & Dohme. Isentress (raltegravir) film-coated tablets and chewable tablets prescribing information. Whitehouse Station, NJ; 2012 Apr.
350. Frelinger AL, Lee RD, Mulford DJ et al. A randomized, 2-period, crossover design study to assess the effects of dexlansoprazole, lansoprazole, esomeprazole, and omeprazole on the steady-state pharmacokinetics and pharmacodynamics of clopidogrel in healthy volunteers. J Am Coll Cardiol. 2012; 59:1304-11. [PubMed 22464259]
351. Angiolillo DJ, Gibson CM, Cheng S et al. Differential effects of omeprazole and pantoprazole on the pharmacodynamics and pharmacokinetics of clopidogrel in healthy subjects: randomized, placebo-controlled, crossover comparison studies. Clin Pharmacol Ther. 2011; 89:65-74. [PubMed 20844485]
More about lansoprazole
- Other brands: Prevacid